GlobalBioenergies' Board of Directors yesterday approved the company's annual accounts for 2022, which show a "controlled" loss of 12 million euros.

Annual sales of 0.7 million euros include 98,000 euros in sales of LAST make-up products and 600,000 euros in sales split between sales of Isonaturane samples, deliveries of isobutene derivatives and various services, including a research contract initiated with Shell.

Sales in 2022 mark a breakthrough, rising from 100,000 to 700,000 euros, without even taking into account the delivery of the first batch of Isonaturane - to L'Oréal, among others - which will take place in the first half of 2023", comments CFO Samuel Dubruque.

Note that operating expenses will fall by more than two million euros between 2021 and 2022. Production at the Pomacle unit has enabled inventories to be valued, thus lowering industrialization and marketing expenses by 1.4 million euros.

Other expense items continue to decrease year-on-year, while headcount has risen from an average of 45.8 employees in 2021 to 48.8 employees in 2022.

Finally, Global Bionergies had a gross cash position of 8.8 million euros on December 31.

Copyright (c) 2023 CercleFinance.com. All rights reserved.